Research and Development (R&D)
The vision of our founder Giacomo Chiesi, an innovative pharmacist from Parma, was that the efficacy of a drug is not only determined by the active ingredient but that the way this molecule is presented to the body is just as important. The latter is often called the formulation of a drug.
Chiesi invested € 381 million in R&D in 2018, equating to more than € 1 million per day.
This investment in R&D represents 21.6% of total group revenues, meaning a continuing growth in R&D in both absolute and relative terms.
Chiesi’s R&D is led from our main facility – an award-winning, state-of-the-art center at our corporate headquarters in Parma, Italy. Our additional six facilities across the world operate in a highly integrated manner, collaborating and sharing knowledge to contribute to the ongoing success of our pipeline.
The stem cell research institute 'Holostem Terapie Avanzate', founded in 2008, is one of the largest research centers in Europe for 'advanced therapies'. In this center, the stem cell technology of the future is being developed in collaboration with scientists from the University of Modena (Italy).